Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs generally are looking for serious growth.…
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top names rated…
MannKind has a serious victory within its grasp. The company has struggled to get its Afrezza inhalable insulin to market for years, and that dream now seems to be within its grasp.
ThinkstockMannKind Corp. (NASDAQ: MNKD)had been trading as though the stock was bracing for an U.S. Food and Drug Administration (FDA) panel decision recommending against the approval of its inhalable insulin called Afrezza. On Tuesday…
ThinkstockThe first question anyone might ask if a stock falls from more than $9 to less than $2.50 is whether it already imploded? Prana Biotechnology Ltd. (NASDAQ: PRAN) has done just that in the…
Teva Pharmaceutical shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent on its top-selling multiple-sclerosis drug.
Prana Biotechnology announced Monday morning that top-line results for a Phase II trial of its Alzheimer drug failed to meet its primary endpoint. Shares were slammed in premarket trading.
Baxter International is taking an activist investor role of its own. The health care company has announced that it is splitting itself into two separate companies.
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage of the…
ThinkstockThe House of Representatives may be single-handedly saving the lab companies in America on Wednesday. A bill was posted to propose a short-term fix to the sustainable growth rate, delaying cuts to Medicare reimbursement…
Exelixis may have a while longer before it gets to be a serious revenue stage company. Its stock was crushed on Wednesday, and the company has lost its $1 billion market cap.
Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone rangers when it came to the carnage. While…
When a drug trial goes bad, the hit to a drug maker's stock is instant and spectacular. Wednesday it will be Insmed in the spotlight. Shares were down nearly 25% in premarket trading.
After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early March, especially in Celgene, Medivation and Pharmacyclics.
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a perfect entry…